KYMR (Kymera Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by KYMR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-27 | Terence Rooney | Chief Medical Officer | A | — | — |
| 2026-07-07 | Nello Mainolfi | Chief Executive Officer | MIXED | — | — |
| 2026-07-02 | Noah Goodman | Chief Business Officer | Sell | — | — |
| 2026-07-02 | Nello Mainolfi | Chief Executive Officer | MIXED | — | — |
| 2026-07-02 | Bruce Booth | Director | Sell | — | — |
| 2026-07-02 | Bruce N. Jacobs | Chief Financial Officer | MIXED | — | — |
| 2026-06-26 | BIOTECHNOLOGY VALUE FUND II LP | Director | Sell | — | — |
| 2026-06-25 | Gorjan Hrustanovic | Director | A | — | — |
| 2026-06-25 | Elena Ridloff | Director | A | — | — |
| 2026-06-25 | Jeffrey W. Albers | Director | A | — | — |
| 2026-06-25 | Victor Sandor | Director | A | — | — |
| 2026-06-25 | JOHN MARAGANORE | Director | A | — | — |
| 2026-06-25 | Pamela Esposito | Director | A | — | — |
| 2026-06-25 | Noah Goodman | Chief Business Officer | MIXED | — | — |
| 2026-06-25 | Bruce Booth | Director | A | — | — |
| 2026-06-25 | Baker Bros. Advisors (GP) LLC | Director | A | — | — |
| 2026-06-25 | Bruce Booth | Director | Sell | — | — |
| 2026-06-25 | Bruce Booth | Director | Sell | — | — |
| 2026-06-25 | BVF II GP LLC | Director | A | — | — |
| 2026-06-22 | Noah Goodman | Chief Business Officer | MIXED | — | — |
| 2026-06-22 | Bruce Booth | Director | MIXED | — | — |
| 2026-06-22 | Bruce Booth | Director | Sell | — | — |
| 2026-06-03 | Bruce N. Jacobs | Chief Financial Officer | M | — | — |
| 2026-05-27 | Jeremy G Chadwick | Chief Operating Officer | Sell | — | — |
| 2026-05-19 | Bruce N. Jacobs | Chief Financial Officer | M | — | — |
| 2026-05-19 | Pamela Esposito | Director | M | — | — |
| 2026-05-11 | Elena Ridloff | Director | MIXED | — | — |
| 2026-04-29 | Nello Mainolfi | Chief Executive Officer | MIXED | — | — |
| 2026-04-24 | Jeremy G Chadwick | Chief Operating Officer | MIXED | — | — |
| 2026-04-24 | Bruce Booth | Director | MIXED | — | — |
| 2026-04-16 | Noah Goodman | Chief Business Officer | Sell | — | — |
| 2026-04-16 | Bruce Booth | Director | MIXED | — | — |
| 2026-04-16 | Jeremy G Chadwick | Chief Operating Officer | MIXED | — | — |
| 2026-04-10 | Noah Goodman | Chief Business Officer | MIXED | — | — |
| 2026-04-01 | Elena Ridloff | Director | MIXED | — | — |
| 2026-04-01 | Jeremy G Chadwick | Chief Operating Officer | MIXED | — | — |
| 2026-03-25 | Jeremy G Chadwick | Chief Operating Officer | MIXED | — | — |
| 2026-03-20 | Pamela Esposito | Director | MIXED | — | — |
| 2026-03-11 | Jeremy G Chadwick | Chief Operating Officer | MIXED | — | — |
| 2026-03-04 | Nello Mainolfi | Chief Executive Officer | A | — | — |
| 2026-03-04 | Noah Goodman | Chief Business Officer | A | — | — |
| 2026-03-04 | Bruce Booth | Director | Sell | — | — |
| 2026-03-04 | Brian Adams | Chief Legal Officer | A | — | — |
| 2026-03-04 | Jared Gollob | Chief Medical Officer | MIXED | — | — |
| 2026-03-04 | Jeremy G Chadwick | Chief Operating Officer | MIXED | — | — |
| 2026-03-04 | Bruce N. Jacobs | Chief Financial Officer | MIXED | — | — |
| 2026-02-25 | Nello Mainolfi | Chief Executive Officer | MIXED | — | — |
| 2026-02-20 | Pamela Esposito | Director | MIXED | — | — |
| 2026-01-20 | Pamela Esposito | Director | MIXED | — | — |
| 2026-01-06 | Nello Mainolfi | Chief Executive Officer | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 7,955,916 | — |
| — | 10%+ Owner | 6,784,648 | — |
| — | 10%+ Owner | 6,070,083 | — |
| — | 10%+ Owner | 5,879,854 | — |
| — | 10%+ Owner | 5,812,200 | — |
| — | 10%+ Owner | 5,763,012 | — |
| — | Director | 2,552,306 | — |
| — | Director | 2,192,249 | — |
| — | Director | 1,888,351 | — |
| — | Director | 1,671,048 | — |
| — | 10%+ Owner | 1,630,660 | — |
| — | Director | 1,466,364 | — |
| — | — | 1,359,109 | — |
| — | 10%+ Owner | 959,211 | — |
| — | Chief Executive Officer | 716,568 | — |
| — | Director | 534,134 | — |
| — | Director | 484,057 | — |
| — | Director | 475,805 | — |
| — | 10%+ Owner | 467,932 | — |
| — | Director | 353,412 | — |
| — | Chief Financial Officer | 320,492 | — |
| — | Director | 294,632 | — |
| — | Director | 294,632 | — |
| — | Director | 294,632 | — |
| — | Chief Medical Officer | 117,581 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KYMR quote page; the site-wide leaderboard is on the insider transactions hub.